Article
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Breast cancer research and treatment - 1 Oct 2014
Vulsteke C, Pfeil A M, Schwenkglenks M, Pettengell R, Szucs T D, Lambrechts D, Peeters M, van Dam P, Dieudonné A S, Hatse S, Neven P, Paridaens R, Wildiers H
Abstract excerpt
To assess the impact of patient-related factors, including genetic variability in genes involved in the metabolism of chemotherapeutic agents, on breast cancer-specific survival (BCSS) and recurrence-free interval (RFI). We selected early breast cancer patients treated between 2000 and 2010 with 4-6 cycles of (neo-)adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) or 3 cycles FEC followed by 3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.